Literature DB >> 22341396

Comparative study of fusion rate induced by different dosages of Escherichia coli-derived recombinant human bone morphogenetic protein-2 using hydroxyapatite carrier.

Jae Hyup Lee1, Chang Hun Yu, Jae Jun Yang, Hae-Ri Baek, Kyung-Mee Lee, Tae-Young Koo, Bong-Soon Chang, Choon-Ki Lee.   

Abstract

BACKGROUND CONTEXT: Hydroxyapatite (HA) is considered to be useful because of its high affinity for recombinant human bone morphogenetic protein (rhBMP), mechanical resistance to compressive force, and possible reduction of rhBMP dose.
PURPOSE: To evaluate the osteoinductivity of Escherichia coli-derived rhBMP-2 and the suitability of porous HA as an rhBMP-2 carrier. STUDY
DESIGN: In vivo study using microcomputerized tomography (micro-CT) scanning. PATIENT SAMPLE: Seventy-six New Zealand white male rabbits were randomized into a single control group (n=14) without rhBMP-2 and four experimental groups (10 μg, 50 μg, 200 μg, and 500 μg of rhBMP-2; n=14 in each group). The subjects were divided into 3- and 6-week groups. OUTCOME MEASURES: Outcome was evaluated by radiography, bending test, three-dimensional micro-CT, and histologic examinations.
METHODS: Bilateral posterolateral fusion was carried out, and rhBMP-2 (0, 10, 50, 200, 500, 1,000, and 2,000 μg) was implanted into the bilateral transverse processes using HA as a carrier.
RESULTS: The fusion rates of the 3-week group were 83.3% for 50 and 200 μg of rhBMP-2 and 100% for 500 μg. The improved fusion rates of the 50 μg or higher groups compared with those of control were statistically significant. The fusion rates of the 6-week group were 75% for 10 μg of rhBMP-2 and 100% for 50 μg or higher. Similarly, the improved fusion rates of the 10 μg or higher groups compared with those of control were statistically significant. Significantly higher percent volumes were observed in the 3-week 200 μg of rhBMP-2 group and 6-week 200 μg of rhBMP-2 group than the 3-week HA group and 6-week HA group, respectively. Trabecular thickness was significantly higher in the 3-week 200 μg of rhBMP-2 group than the 3-week HA group. Histologic analysis of the 10 μg group showed bone tissues within the pores from 3 weeks, and this was observed more vividly in the 50, 200, and 500 μg groups. The 6-week 10 μg and 50 μg of rhBMP-2 groups had lower amounts of new tissue but higher portions of complete bone tissue within the HA specimen, along with higher formation of completely reconstituted bone tissues outside HA.
CONCLUSIONS: Injection of 50 μg or more of E. coli-derived rhBMP-2 into a HA carrier induced earlier bone fusion in the intertransverse process of rabbits, which confirms the excellent bone forming ability of E. coli-derived rhBMP-2 and the suitability of HA as a carrier of rhBMP-2.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341396     DOI: 10.1016/j.spinee.2012.01.013

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  11 in total

Review 1.  Clinical effect of hyperbaric oxygen therapy in the treatment of femoral head necrosis : A systematic review and meta-analysis.

Authors:  Wei Li; Ziliang Ye; Wei Wang; Kun Wang; Lang Li; Dewei Zhao
Journal:  Orthopade       Date:  2017-05       Impact factor: 1.087

2.  Osteogenic activity of silver-loaded coral hydroxyapatite and its investigation in vivo.

Authors:  Yu Zhang; Qing-Shui Yin; Chu-Song Zhou; Hong Xia; Ying Zhang; Yan-Peng Jiao
Journal:  J Mater Sci Mater Med       Date:  2014-01-14       Impact factor: 3.896

3.  Effects of porous beta-tricalcium phosphate-based ceramics used as an E. coli-derived rhBMP-2 carrier for bone regeneration.

Authors:  Jae Hyup Lee; Mi Young Ryu; Hae-Ri Baek; Kyung Mee Lee; Jun-Hyuk Seo; Hyun-Kyung Lee; Hyun-Seung Ryu
Journal:  J Mater Sci Mater Med       Date:  2013-06-01       Impact factor: 3.896

4.  Synergistic induction of early stage of bone formation by combination of recombinant human bone morphogenetic protein-2 and epidermal growth factor.

Authors:  Jae Hyup Lee; Soo-Jeong Jang; Hae-Ri Baek; Kyung Mee Lee; Bong-Soon Chang; Choon-Ki Lee
Journal:  J Tissue Eng Regen Med       Date:  2014-04-25       Impact factor: 3.963

5.  Acute Intravenous Injection Toxicity Study of Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 in Rat.

Authors:  Jae Hyup Lee; Eui-Nam Lee; Bong-Soon Chang; Choon-Ki Lee
Journal:  Asian Spine J       Date:  2014-04-08

6.  Reconstruction of radial bone defect using gelatin sponge and a BMP-2 combination graft.

Authors:  Seong-Gon Kim; Jae-Hwan Jeong; Xiangguo Che; Yong-Tae Park; Sang-Woon Lee; Eun-Sun Jung; Senyon Choe; Je-Yong Choi
Journal:  BMB Rep       Date:  2013-06       Impact factor: 4.778

7.  Effects of the combination of bone morphogenetic protein-2 and nano-hydroxyapatite on the osseointegration of dental implants.

Authors:  KangMi Pang; Young-Kwon Seo; Jong-Ho Lee
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2021-12-31

8.  Long-term posterolateral spinal fusion in rabbits induced by rhBMP6 applied in autologous blood coagulum with synthetic ceramics.

Authors:  Nikola Stokovic; Natalia Ivanjko; Marko Pecin; Igor Erjavec; Ana Smajlović; Marina Milesevic; Sven Karlovic; Hrvoje Capak; Zoran Vrbanac; Drazen Maticic; Slobodan Vukicevic
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

9.  Synthetic ceramic macroporous blocks as a scaffold in ectopic bone formation induced by recombinant human bone morphogenetic protein 6 within autologous blood coagulum in rats.

Authors:  Nikola Stokovic; Natalia Ivanjko; Marina Milesevic; Ivona Matic Jelic; Kristian Bakic; Viktorija Rumenovic; Hermann Oppermann; Larry Shimp; T Kuber Sampath; Marko Pecina; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2020-10-14       Impact factor: 3.075

10.  Interbody fusion in degenerative lumbar spinal stenosis with additional posterolateral fusion using Escherichia coli-derived bone morphogenetic protein-2: A Pilot study.

Authors:  Sung Hoon Choi; Ja Wook Koo; DaeHyun Choe; Jeong Min Hur; Dong-Hong Kim; Chang-Nam Kang
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.